Profile data is unavailable for this security.
About the company
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-47.99m
- Incorporated1998
- Employees40.00
- LocationViracta Therapeutics Inc2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA 92007United StatesUSA
- Phone+1 (858) 400-8470
- Fax+1 (650) 266-3501
- Websitehttps://www.viracta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | 0.00 | -31.48m | 27.15m | 9.00 | -- | 0.7665 | -- | -- | -1.19 | -1.19 | 0.00 | 0.9719 | 0.00 | -- | -- | 0.00 | -77.74 | -72.06 | -84.92 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.30m | 3.00 | -- | 1.04 | -- | 63.29 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| NKGen Biotech Inc | 0.00 | -82.95m | 28.34m | 63.00 | -- | -- | -- | -- | -5.24 | -5.24 | 0.00 | -2.68 | 0.00 | -- | -- | 0.00 | -86.93 | -- | -111.69 | -- | -- | -- | -- | -- | -- | -0.6077 | -- | -- | -- | -- | -1,923.83 | -- | -- | -- |
| Lipocine Inc | -2.85m | -16.35m | 28.45m | 17.00 | -- | 1.39 | -- | -- | -3.11 | -3.11 | -0.5417 | 3.83 | -0.0942 | -- | -- | -167,695.30 | -54.02 | -39.32 | -58.16 | -45.87 | -- | -- | -- | -442.26 | -- | -- | 0.00 | -- | -670.16 | -- | -51.99 | -- | -- | -- |
| America Great Health | 219.13k | -859.20k | 29.56m | 7.00 | -- | -- | -- | 134.89 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 29.85m | 40.00 | -- | 5.30 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| Aprea Therapeutics Inc | 583.24k | -14.29m | 30.35m | 7.00 | -- | 1.23 | -- | 52.05 | -4.00 | -4.00 | 0.1613 | 4.89 | 0.0221 | -- | -- | 83,320.00 | -54.11 | -68.66 | -63.19 | -77.19 | -- | -- | -2,449.55 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Singular Genomics Systems Inc | 2.91m | -94.82m | 30.44m | 255.00 | -- | 0.1698 | -- | 10.46 | -1.30 | -1.30 | 0.04 | 2.42 | 0.0098 | 0.2182 | 3.94 | 11,415.69 | -31.96 | -- | -33.80 | -- | -19.17 | -- | -3,257.30 | -- | 9.77 | -- | 0.0474 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -17.19m | 31.16m | 29.00 | -- | -- | -- | -- | -0.4079 | -0.4079 | 0.00 | -0.0803 | 0.00 | -- | -- | 0.00 | -271.62 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Dare Bioscience Inc | 2.81m | -30.16m | 31.23m | 23.00 | -- | -- | -- | 11.12 | -0.3444 | -0.3444 | 0.032 | -0.0505 | 0.0863 | -- | 2.12 | 122,082.20 | -92.65 | -109.51 | -463.87 | -246.26 | -- | -- | -1,074.17 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Mink Therapeutics Inc | 0.00 | -22.46m | 31.23m | 31.00 | -- | -- | -- | -- | -0.6538 | -0.6538 | 0.00 | -0.5219 | 0.00 | -- | -- | 0.00 | -172.59 | -- | -2,317.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -30.16m | 32.09m | 2.00 | -- | -- | -- | -- | -2.95 | -2.95 | 0.00 | -0.1398 | 0.00 | -- | -- | -- | -182.00 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -14.58m | 32.12m | 4.00 | -- | 6.29 | -- | -- | -1.14 | -1.14 | 0.00 | 0.3226 | 0.00 | -- | -- | 0.00 | -170.64 | -- | -243.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Fortress Biotech Inc | 84.51m | -68.67m | 32.12m | 186.00 | -- | 1.12 | -- | 0.3801 | -8.88 | -8.88 | 10.29 | 1.49 | 0.366 | 2.19 | 3.89 | 454,371.00 | -66.76 | -52.50 | -117.74 | -99.46 | 68.45 | 63.17 | -182.40 | -236.94 | 1.26 | -11.31 | 0.9758 | -- | 11.58 | 25.75 | 27.42 | -- | -9.37 | -- |
Data as of May 10 2024. Currency figures normalised to Viracta Therapeutics Inc's reporting currency: US Dollar USD
21.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 3.61m | 9.20% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.52m | 3.87% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.15m | 2.94% |
| Laurion Capital Management LPas of 31 Dec 2023 | 563.00k | 1.43% |
| MAI Capital Management LLCas of 31 Mar 2024 | 364.10k | 0.93% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 298.44k | 0.76% |
| Aisling Capital Management LPas of 31 Dec 2023 | 288.57k | 0.74% |
| Medical Strategy GmbHas of 30 Nov 2023 | 278.12k | 0.71% |
| Geode Capital Management LLCas of 31 Dec 2023 | 252.70k | 0.64% |
| Apo Asset Management GmbHas of 30 Sep 2023 | 252.15k | 0.64% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
